Search Results - "O'Connell, Casey Lee"

Emerging treatment options for myelofibrosis: focus on pacritinib by Chow, Vivian, Weissman, Ashley, O'Connell, Casey Lee, Mehrvar, Azim, Akhtari, Mojtaba

“…Myelofibrosis (MF) is a myeloid malignancy associated with a heavy symptomatic burden that decreases quality of life and presents a risk for leukemic…”
Get full text

Symptoms adversely impact survival among patients with cancer and unsuspected pulmonary embolism by O'Connell, Casey Lee, Razavi, Pedram A, Liebman, Howard A

Get full text

A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS) by Luger, Selina M., O'Connell, Casey Lee, Klimek, Virginia, Cooper, Maureen A., Besa, Emmanuel C., Rossetti, James M., Reid, Gregory K., Humphrey, Rachel, Martell, Robert E., Garcia-Manero, Guillermo

“…Abstract only 7116 Background: Mocetinostat (MGCD0103) is an orally available, isotype-selective, non-hydroxamate HDAC inhibitor targeting HDACs 1,2, 3 and 11…”
Get full text

First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML) by Griffiths, Elizabeth A., Kantarjian, Hagop M., Roboz, Gail J., Kropf, Patricia Lamont, O'Connell, Casey Lee, Yee, Karen W. L., Garcia-Manero, Guillermo, Jabbour, Elias, Feldman, Eric Jay, Walsh, Katherine Jean, Rizzieri, David, Stock, Wendy, Lunin, Scott D., Naim, Sue, Choy, Gavin S., Taverna, Pietro, Hao, Yong, Azab, Mohammad, Chung, Woonbok, Issa, Jean-Pierre J.

“…Abstract only…”
Get full text